SK biopharmaceuticals Co., Ltd.
Financials
Valuation Metrics
SK biopharmaceuticals Co., Ltd.'s Market Cap is ₩6.2T. At end of 2025 it was ₩9.8T. Ranked #87 of 2,436 in KR market (top 4%), #82 of 787 on KOSPI (top 10%), #5 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 6.25T KRW | KR#87/2,436 Sec#5/234 |
| Revenue | 790.25B KRW | KR#457/2,436 Sec#19/234 |
| Net Income | 336.37B KRW | KR#95/2,436 Sec#3/234 |
| Total Assets | 1.32T KRW | KR#395/2,436 Sec#19/234 |
| Net Assets | 932.05B KRW | KR#296/2,436 Sec#18/234 |
| Employees | 265 | KR#883/2,436 Sec#74/234 |
| Value | ||
| P/E | 18.58x | KR#1,076/2,436 Sec#65/234 |
| P/B | 6.71x | KR#2,290/2,436 Sec#193/234 |
| PEG | 0.04x | KR#243/2,436 Sec#12/234 |
| P/S | 7.91x | KR#2,239/2,436 Sec#154/234 |
| EV/EBITDA | 22.16x | KR#1,065/2,436 Sec#64/234 |
| FCF Yield | 2.71% | KR#1,019/2,436 Sec#67/234 |
| Profitability | ||
| ROE | 36.09% | KR#25/2,436 Sec#1/234 |
| ROA | 25.47% | KR#17/2,436 Sec#3/234 |
| Op. Margin | 33.92% | KR#36/2,436 Sec#9/234 |
| Revenue Growth | 57.84% | KR#250/2,436 Sec#27/234 |
| Earnings Growth | 423.55% | KR#129/2,436 Sec#9/234 |
| Financial Health | ||
| Debt Ratio | 41.67% | KR#152/2,436 Sec#20/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | 169.44B KRW | KR#125/2,436 Sec#4/234 |
| Cash | 308.99B KRW | KR#202/2,436 Sec#4/234 |
| Current Ratio | 2.49x | KR#758/2,436 Sec#93/234 |
| Net Debt/EBITDA | -1.15x | KR#433/2,436 Sec#24/234 |
| Performance | ||
| 1Y Return | -16.96% | KR#1,169/2,436 Sec#90/234 |
| 1M Return | -7.42% | KR#1,586/2,436 Sec#161/234 |
| From 52W High | -44.62% | KR#958/2,436 Sec#74/234 |
| 1Y MDD | -46.98% | KR#789/2,436 Sec#68/234 |
| Trading | ||
| Volume | 119,361 shares | KR#836/2,436 Sec#82/234 |
| Foreign Own. | 12.54% | KR#394/2,436 Sec#34/234 |
| Per Share | ||
| EPS | 4,454 KRW | KR#194/2,436 Sec#14/234 |
| BPS | 11,902 KRW | KR#829/2,436 Sec#60/234 |
Company Info
SK Biopharm was newly established in 2011 through a spin-off of SK Co., Ltd.'s Life Science business division, having initiated new drug research and development in 1993. It launched cenobamate and solriamfetol, treatments for central nervous system epilepsy and sleep disorders, following U.S. FDA approval, and has signed technology export contracts with 17 countries. The company is expanding its CNS capabilities into oncology using RPT and TPD technologies and pursues new drug development through an AI drug design platform and a partnership with LifeSci Venture Partners. SK Biopharm is headquartered in Seongnam-si, Gyeonggi-do.